1. AB1182 Efficacy and safety of canakinumab, fully human anti-interleukin-1beta antibody, in systemic juvenile idiopathic arthritis. (23rd January 2014) Authors: Ruperto, N.; Brunner, H.; Quartier, P.; Constantin, T.; Wulffraat, N.; Horneff, G.; Brik, R.; McCann, L.; Kasapcopur, O.; Rutkowska-Sak, L.; Schneider, R.; Berkun, Y.; Calvo, I.; Erguven, M.; Goffin, L.; Hofer, M.; Kallinich, T.; Knupp, S.; Uziel, Y.; Viola, S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. (23rd January 2014) Authors: De Benedetti, F.; Brunner, H.; Ruperto, N.; Kenwright, A.; Devlin, C.; Calvo, I.; Cuttica, R.; Ravelli, A.; Schneider, R.; Eleftheriou, D.; Wouters, C.; Xavier, R.; Zemel, L.; Baildam, E.; Burgos-Vargas, R.; Dolezalova, P.; Garay, S.M.; Joos, R.; Grom, A.; Wulffraat, N. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 425 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy. (10th June 2014) Authors: Brachat, A.; Grom, A.; Wulffraat, N.; Brunner, H.; Quartier, P.; Brik, R.; McCann, L.; Ozdogan, H.; Rutkowska-Sak, L.; Schneider, R.; Gerloni, V.; Harel, L.; Terreri, M.; Houghton, K.; Joos, R.; Kingsbury, D.; Lopez-Benitez, J.; Bek, S.; Schumacher, M.; Valentin, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0012 Microrna Associated with Active Systemic Juvenile Idiopathic Arthritis Regulate CD163 Expression in Polarized Macrophages through Two Distinct Mechanisms. (15th July 2016) Authors: Thornton, S.; Do, T.D.; Tan, R.; Sproles, A.; Bennett, M.; Medvedovic, M.; DeLay, M.; Shen, N.; Grom, A.; Schulert, G. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients. (10th June 2014) Authors: Quartier, P.; Grom, A.; Ruperto, N.; Brunner, H.; Schikler, K.; Erguven, M.; Goffin, L.; Hofer, M.; Kallinich, T.; Marzan, K.; Gaillez, C.; Lheritier, K.; Abrams, K.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0283 Microrna 125A-5P has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro. (9th June 2015) Authors: Schulert, G.; Fall, N.; Shen, N.; Thornton, S.; Grom, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0290 EMAPALUMAB (ANTI-INTERFERON-GAMMA MONOCLONAL ANTIBODY) IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). (2nd June 2020) Authors: De Benedetti, F.; Brogan, P.; Bracaglia, C.; Pardeo, M.; Marucci, G.; Sacco, E.; Eleftheriou, D.; Papadopoulou, C.; Grom, A.; Quartier, P.; Schneider, R.; Jacqmin, P.; Frederiksen, R.; Ballabio, M.; De Min, C. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. SAT0483 Tapering and Withdrawal of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results from an Alternative Dosing Regimen in the Tender Study. (9th June 2015) Authors: De Benedetti, F.; Ruperto, N.; Brunner, H.; Grom, A.; Wulffraat, N.; Henrickson, M.; Jerath, R.; Kimura, Y.; Kadva, A.K.; Keane, C.; Wang, J.; Wimalasundera, S.; Gokani, P.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 835 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0508 Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 5-Year Data from Tender, A Phase 3 Clinical Trial. (9th June 2015) Authors: De Benedetti, F.; Ruperto, N.; Brunner, H.; Keane, C.; Wells, C.; Wang, J.; Calvo, I.; Cuttica, R.; Ravelli, A.; Schneider, R.; Eleftheriou, D.; Wouters, C.; Xavier, R.; Zemel, L.; Baildam, E.; Burgos-Vargas, R.; Dolezalova, P.; Garay, S.M.; Joos, R.; Grom, A. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗